

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Predictmedix Inc. (formerly, Cultivar Holdings Inc.) (the "Issuer" or "Predictmedix").

Trading Symbol: CSE: PMED; OTCQB: PMEDF

Number of Outstanding Listed Securities: 100,166,649

Date: July 10, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Sales Contract for the Caribbean Region along with strategic appointments and key partnership

On June 4, 2020 the Issuer announced the execution of a sales contract for its COVID-19 screening technology for the Caribbean region and the execution of a

sales contract with Caribbean Digital Media Academy ("CDMA"), a services integrator company registered in Jamaica. Additionally, the Issuer announced the appointment of Mr. Prabhakar Srivastava, a senior healthcare executive, to assist with the Issuer's business development and strategy and Dr. Deepu Banerji, a neurosurgeon, to help the Issuer develop its artificial intelligence ("AI") technology.

The Issuer will continue to develop its AI powered technologies to assist with the diagnosis and management of mental health disorders including depression, autism, ADHD and dementia. In connection with this initiative, and on June 4, 2020, Predictmedix also announced entering into a partnership with Max Healthcare.

2. Provide a general overview and discussion of the activities of management.

The Issuer's management continues to work towards the initiatives described in #1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Issuer will continue to develop the technology described in #1 above.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Predictmedix announced a collaboration with Tech Mahindra Ltd (not related to the issuer), a leading provider of digital transformation, consulting and business re-engineering services, to offer AI-Based Healthcare solutions as a part of suite of post-COVID-19 technology. The COVID-19 pandemic has brought upon significant disruption to the global economy which has impacted all the major industries and has highlighted the importance of workplace safety. In keeping with the lines of workplace safety, Tech Mahindra is assembling a suite of technologies which will have a relevance in a post-COVID-19 environment from the context of workplace health and safety.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Predictmedix announced the acquisition of MobileWellbeing, an innovative, feature rich, Telemedicine Remote Patient Monitoring platform that will integrate with Predictmedix's Artificial Intelligence ("AI") driven rapid screening system for infectious diseases, including COVID-19. This will also integrate with the Company's screening modules for impairment and mental illness. The MobileWellbeing platform addresses several of the gaps currently observed with comparable platforms which are offered by a few public companies trading at high valuations. MobileWellbeing is being acquired by Predictmedix (asset purchase) for an upfront cash payment of \$25,000 along with 250,000 common shares and a royalty of 20 percent of gross sales from the first \$2.5 million in sales generated exclusively from the MWB platform. Among 250,000 shares, 150,000 common shares are to be vested with sales related milestones. At the same time, the CEO of MobileWellbeing, Mr. Rajiv Muradia will join the board of Predictmedix as a technical advisor. The transaction is expected to close within the next 60 days.

Describe the acquisition of new customers or loss of customers.

Not applicable.

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable.

9. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

10. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

11. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

12. Provide details of any securities issued and options or warrants granted.

Not applicable.

13. Provide details of any loans to or by Related Persons.

Not applicable.

14. Provide details of any changes in directors, officers or committee members.

Not applicable.

15. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer's large scale study for its prediction technology continues to be progressing well. The Issuer believes that enhancing its Predictmedix division is a positive trend for the Issuer and its shareholders, and in particular, in light of the global COVID-19 pandemic.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 10, 2020.

Rahul Kushwah
Name of Director or Senior Officer

/s/ Rahul Kushwah
Signature

COO
Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer		YY/MM/DD
Predictmedix Inc.	June 30, 2020	20/07/10
Issuer Address		
3000 - 77 King Street West		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Toronto, Ontario, M5K 1G8	N/A	(647) 889-6916
Contact Name	Contact Position	Contact Telephone No.
Dr. Rahul Kushwah	COO	(647) 889-6916
Contact Email Address	Web Site Address	
rahul.kushwahphd@gmail.com	https://www.predictmedix.com/	